Ikarian Capital’s Capricor Therapeutics CAPR Stock Holding History

Ikarian Capital’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.6M	Buy	+350,000	New	+$9.33M	0.86%	32
2025 Q4	–	Sell	-100,000	Closed	-$721K	–	187
2025 Q3	$721K	Sell	100,000 -600,000	-86%	-$4.42M	0.07%	129
2025 Q2	$6.95M	Buy	700,000 +300,000	+75%	+$3.17M	1.34%	27
2025 Q1	$3.8M	Buy	400,000 +38,900	+11%	+$540K	0.47%	44
2024 Q4	$4.98M	Buy	361,100 +61,100	+20%	+$1.07M	0.68%	41
2024 Q3	$4.56M	Buy	+300,000	New	+$1.48M	0.64%	45

Other funds holding CAPR

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JHC

Jones Hill Capital New York $466M AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ikarian Capital's CAPR Position: Q1 2026 in Review

Ikarian Capital reduced its Capricor Therapeutics (CAPR) stake by 8.7% in Q1 2026, selling an estimated $1.33M and leaving 528,015 shares worth $16.1M. The position accounts for 1.3% of the portfolio, ranked #18.

Ikarian Capital first reported a position in CAPR in Q3 2024 and has held it in 4 quarters since. The position peaked at $16.7M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

Ikarian Capital held 528,015 shares of Capricor Therapeutics worth $16.1M as of Q1 2026.
Ikarian Capital sold 50,000 Capricor Therapeutics shares in Q1 2026, an estimated $1.33M.
Capricor Therapeutics made up 1.3% of Ikarian Capital's portfolio in Q1 2026, its #18 holding.
Ikarian Capital first reported a position in Capricor Therapeutics in Q3 2024 and has held it in 4 quarters since.
Ikarian Capital's Capricor Therapeutics position peaked at $16.7M in Q4 2025.
177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.